NCT00390936View on ClinicalTrials.gov

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Solid Tumors
Interventions
DRUG

Brivanib

Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity

Trial Locations (1)

411-8777

Local Institution, Sunto-Gun

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00390936 - A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter